We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
Product News

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
Product News

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

Credit: rawpixel

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Intravacc, a company with expertise in translational research and development of viral and bacterial vaccines, and Celonic Group, a biopharmaceutical contract development and manufacturing organization (CDMO), specialized in development and production of Advanced Therapy Medicinal Products (ATMP) and mammalian cell lines expressed bio-therapeutics, have announced that they have signed a research agreement to further design, develop and produce a COVID-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc’s proprietary Outer Membrane Vesicle (OMV) technology.

In the beginning of March this year, Intravacc started working on the development of four candidate coronavirus vaccines based on three proprietary technologies: Vero cell, OMV and iBoost.

For this specific joint vaccine development, Intravacc combines its safe and immunogenic OMV delivery platform with S-proteins expressed by Celonic Group’s industry-leading CHOvolution® mammalian cell expression system, in order to generate a highly effective and balanced B and T cell response against SARS-CoV-2. Swiss based Celonic Group will construct cell lines producing the S-protein in high quantities and develop a GMP production process. Preclinical studies will start shortly to select the best candidate protein for the vaccine. The collaboration aims to accelerate development of Intravacc’s COVID-19 OMV protein vaccine, which is expected to enter clinical testing in 2021.

Dr. Jan Groen, Intravacc’s Chief Executive Officer of Intravcc said: “Several studies have shown that OMVs have the ability to enhance the immune response and can be relatively easy formulated with target specific peptides and proteins. This, combined with the fact they can be quickly scaled-up for manufacturing, makes it an ideal suited platform under the current circumstances where quantity and speed are critical.”

Dr. Konstantin Matentzoglu, Chief Executive Officer of Celonic, adds: “At Celonic, we are thrilled to join hands with Intravacc in the fight against this worldwide pandemic. The novel vaccine has the potential to prevent morbidity and mortality of COVID-19. Together, we have an opportunity to make a difference in the lives of patients at this time of great need.”

Advertisement